Premium
Treatment of Primary Pulmonary Hypertension
Author(s) -
Hirth Karen E,
Williams Trevor J
Publication year - 2002
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/jppr2002323185
Subject(s) - medicine , sildenafil , treprostinil , bosentan , pulmonary hypertension , life expectancy , intensive care medicine , quality of life (healthcare) , endothelin receptor , population , receptor , nursing , environmental health
Primary pulmonary hypertension (PPH) is a rare, serious and life threatening disease. Conventional treatments, including anticoagulation and non‐selective vasodilators, may increase survival. However the life expectancy and quality of life for these patients is generally poor. Newer treatments for PPH have become increasingly available in the last few years. Drugs such as epoprostenol, bosentan, treprostinil and sildenafil have now been licensed overseas and used in selected patients in Australia. There is great optimism that these drugs represent a very significant advance in the treatment of PPH.